99mTc-DPD-SPECT/CT对心脏淀粉样变的定量评估
研究纳入136例疑似心脏淀粉样变患者行99mTc-DPD骨显像及胸部SPECT/CT,通过体模研究确定SUV定量缩放因子,在全心脏感兴趣体积内定量心肌摄取。45例诊断为心脏淀粉样变,心脏SUVmax与Perugini评分强相关(Spearman r 0.75,p < 0.0001),SUVmax检测ATTR-CA的AUC为0.96 ± 0.02(p < 0.0001),灵敏度98.7%、特异度87.2%。
要点
- 心脏SUVmax与Perugini评分强相关(Spearman r 0.75,p < 0.0001)。
- SUVmax检测ATTR-CA的AUC为0.96 ± 0.02,灵敏度98.7%、特异度87.2%。
- 随心脏SUVmax和Perugini评分升高,骨摄取降低(p < 0.0001)。
核心结论
- 研究展示了一种易行且准确的SPECT定量方法用于心脏淀粉样变。
- 心脏示踪剂摄取的定量评估可能提高诊断准确性和风险分类。
- 该方法可能有助于ATTR淀粉样变患者的监测和疗效反应评估。
研究设计与样本
- 136例疑似心脏淀粉样变患者接受99mTc-DPD骨显像,含胸部SPECT/CT。
- 进行影像体模研究以确定SPECT/CT的SUV定量缩放因子。
- 在全心脏感兴趣体积内定量心肌示踪剂摄取。
主要发现
- 45例患者诊断为心脏淀粉样变。
- 心脏SUVmax与Perugini评分强相关(Spearman r 0.75,p < 0.0001)。
- 骨内示踪剂摄取随心脏SUVmax和Perugini评分升高而降低(p < 0.0001)。
- ROC分析显示SUVmax检测ATTR-CA性能良好,AUC为0.96 ± 0.02(p < 0.0001),灵敏度98.7%、特异度87.2%。
关键数值与推荐
- 心脏SUVmax与Perugini评分的Spearman相关系数r为0.75(p < 0.0001)。
- SUVmax检测ATTR-CA的AUC为0.96 ± 0.02(p < 0.0001)。
- SUVmax检测ATTR-CA的灵敏度为98.7%、特异度为87.2%。
- 骨内示踪剂摄取随心脏SUVmax和Perugini评分升高而降低(p < 0.0001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Transthyretin (ATTR) amyloidosis is responsible for the majority of cardiac amyloidosis (CA) cases and can be reliably diagnosed with bone scintigraphy and the visual Perugini score. We aimed to implement a quantification method of cardiac amyloid deposits in patients with suspected cardiac amyloidosis and to compare performance to visual scoring. METHODS AND MATERIALS: 136 patients received 99mTc-DPD-bone scintigraphy including SPECT/CT of the thorax in case of suspicion of cardiac amyloidosis. Imaging phantom studies were performed to determine the scaling factor for standardized uptake value (SUV) quantification from SPECT/CT. Myocardial tracer uptake was quantified in a whole heart volume of interest. RESULTS: Forty-five patients were diagnosed with CA. A strong relationship between cardiac SUVmax and Perugini score was found (Spearman r 0.75, p < 0.0001). Additionally, tracer uptake in bone decreased with increasing cardiac SUVmax and Perugini score (p < 0.0001). ROC analysis revealed good performance of the SUVmax for the detection of ATTR-CA with AUC of 0.96 ± 0.02 (p < 0.0001) with sensitivity 98.7% and specificity 87.2%. CONCLUSION: We demonstrate an accessible and accurate quantitative SPECT approach in CA. Quantitative assessment of the cardiac tracer uptake may improve diagnostic accuracy and risk classification. This method may enable monitoring and assessment of therapy response in patients with ATTR amyloidosis.
引用
- Kessler L, Fragoso Costa P, Kersting D, et al. Quantitative 99mTc-DPD-SPECT/CT assessment of cardiac amyloidosis. J Nucl Cardiol. 2022. PMID: 35562639. doi:10.1007/s12350-022-02960-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。